US 12,247,077 B2
Bispecific EGFR/c-Met antibodies
Mark Chiu, Paoli, PA (US); Sheri Moores, Phoenixville, PA (US); Joost Neijssen, Ultrecht (NL); Paul Parren, Ultrecht (NL); and Janine Schuurman, Ultrecht (NL)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Aug. 10, 2021, as Appl. No. 17/398,294.
Application 15/386,195 is a division of application No. 14/283,257, filed on May 21, 2014, granted, now 9,580,508, issued on Feb. 28, 2017.
Application 17/398,294 is a continuation of application No. 16/697,249, filed on Nov. 27, 2019, abandoned.
Application 16/697,249 is a continuation of application No. 15/989,532, filed on May 25, 2018, abandoned.
Application 15/989,532 is a continuation of application No. 15/616,016, filed on Jun. 7, 2017, abandoned.
Application 15/616,016 is a continuation in part of application No. 15/386,195, filed on Dec. 21, 2016, granted, now 9,695,242, issued on Jul. 4, 2017.
Application 14/283,257 is a continuation in part of application No. 14/086,588, filed on Nov. 21, 2013, granted, now 9,593,164, issued on Mar. 14, 2017.
Claims priority of provisional application 61/892,797, filed on Oct. 18, 2013.
Claims priority of provisional application 61/864,717, filed on Aug. 12, 2013.
Claims priority of provisional application 61/809,541, filed on Apr. 8, 2013.
Claims priority of provisional application 61/782,550, filed on Mar. 14, 2013.
Claims priority of provisional application 61/728,912, filed on Nov. 21, 2012.
Prior Publication US 2021/0395373 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 31/437 (2006.01); A61K 31/4545 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 33/243 (2019.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 31/437 (2013.01); A61K 31/4545 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 33/243 (2019.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); A61K 2300/00 (2013.01); C07K 2317/31 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2318/20 (2013.01)] 26 Claims
 
1. An isolated bispecific epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody, comprising:
a) a first heavy chain (HC1) comprising a HC1 constant domain 3 (HC1 CH3) and a HC1 variable region 1 (VH1);
b) a first light chain (LC1) comprising a light chain variable region 1 (VL1);
c) a second heavy chain (HC2) comprising a HC2 constant domain 3 (HC2 CH3) and a HC2 variable region 2 (VH2); and
d) a second light chain (LC2) comprising a light chain variable region 2 (VL2),
wherein the VH1 comprises a heavy chain complementarity determining region 1 (HCDR1), a HCDR2 and a HCDR3 comprising the amino acid sequences of SEQ ID NOs: 210, 211 and 212, respectively; the VL1 comprises a light chain complementarity determining region 1 (LCDR1), a LCDR2 and a LCDR3 comprising the amino acid sequences of SEQ ID NOs: 213, 214 and 215, respectively, the VH2 comprises a HCDR1, a HCDR2 and a HCDR3 comprising the amino acid sequences of SEQ ID NOs: 216, 217 and 218, respectively; and the VL2 comprises a LCDR1, a LCDR2 and a LCDR3 comprising the amino acid sequences of SEQ ID NOs: 219, 220 and 221, respectively.